ScripBayer has secured the first global approval for elinzanetant, trumpeted as a key growth driver for its pharma division in the coming years, after the UK gave the green light to the hot flashes therapy
ScripFollowing up on last year’s approval of Vyloy (zolbetuximab) and looking to build its pipeline of antibody-drug conjugate (ADC) therapies for cancer, Astellas unveiled a licensing agreement with China
Pink SheetContract manufacturing of biologics is one of the few weak points in the typically overwhelming advantage the US holds over Europe in bestowing the first approval for new drug products, a Pink Sheet
ScripPfizer has thrust into the global race for a best-in-class bispecific antibody that inhibits both programmed cell death protein 1/ligand 1 (PD-1/L1) and vascular endothelial growth factor (VEGF) as it